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Inhaled short-acting beta-agonists (SABAs)
are most effective in preventing exercise-
induced bronchoconstriction, followed by
inhaled mast cell stabilizers and anti-
cholinergic agents (strength of 
recommendation [SOR]: A, multiple 
randomized control trials [RCTs]). Less 
evidence supports the use of leukotriene
antagonists and inhaled corticosteroids,
either individually or in combination (SOR:
B). Underlying asthma, which commonly
contributes to exercise-induced 
bronchoconstriction, should be diagnosed
and controlled first (SOR: C).
Control the asthma and the need for pre-
treatment often becomes unnecessary
Because truly isolated exercise-induced
bronchoconstriction is uncommon in a
nonasthmatic child, and because 
bronchospasm in a child during exercise
more commonly indicates undiagnosed
asthma, search for treatable asthma when a
child wheezes with exercise. These children
have sputum eosinophilia reflecting 
inflammation, and they are best served by
addressing the underlying asthma with
inhaled corticosteroids. Once the asthma is
under control, their need for “the best 
pre-treatment” (a SABA) often becomes
irrelevant. Ask the child whether he or she 
is having more shortness of breath and 
difficulty breathing after exercise than 
during exercise; this reveals those most
likely to benefit from treatment.
C L I N I C A L C O M M E N TA R Y
z Evidence summary
It is difficult to interpret studies on exer-
cise-induced bronchoconstriction (the
rather uncommon presence of exercise-
induced bronchospasm in a nonasthmatic)
and exercise-induced asthma (the more
common situation of asthma worsened by
exercise). Many studies include both types
of patients. 
A systematic review of 24 RCTs (of
which 13 evaluated children) showed that
SABAs, mast cell stabilizers, and anti-
cholinergics provide a significant protec-
tive effect against exercise-induced bron-
choconstriction with few adverse effects
(the child subgroup analyses did not differ
significantly from pooled results). Mast
cell stabilizers were found less effective at
attenuating bronchoconstriction than
SABAs, with an average maximum
decrease in the forced expiratory volume in
1 second (FEV1) of 11.9% compared with
4.6% for beta-agonists (child subgroup:
weighted mean difference=7.3%; 95%
 
confidence interval [CI], 3.9–10.7).
Complete protection (defined in this study
as maximum % decrease in FEV1 <15%
post-exercise) and clinical protection (50%
improvement over placebo) measures were
included. Fewer children had complete
protection (pooled: 66% vs 85%, odds
ratio [OR]=0.3; 95% CI, 0.2–0.5) or clini-
cal protection (pooled: 55% vs 77%,
OR=0.4; 95% CI, 0.2–0.8). 
Mast cell stabilizers were more effec-
tive than anticholinergic agents, with aver-
age maximum FEV1 decrease of 9.4%
compared with 16.0% on anticholinergics
(child subgroup: weighted mean differ-
ence=6.6%; 95% CI, 1.0–12.2). They also
provided more individuals with complete
protection (pooled: 73% vs 56%, OR=2.2;
95% CI, 1.3–3.7) and clinical protection
(pooled: 73% vs 52%, OR=2.7; 95% CI,
1.1–6.4). Combining mast cell stabilizers
with SABAs did not produce significant
advantages in pulmonary function over
SABAs alone. No significant subgroup dif-
ferences were seen based on age, severity,
or study quality.1
Another systematic review of 20 RCTs
(15 studying children and 5 studying
adults) with patients aged >6 years showed
that 4 mg of nedocromil (Tilade) inhaled
15 to 60 minutes before exercise signifi-
cantly reduced the severity and duration 
of exercise-induced bronchoconstriction
compared with placebo. It had a greater
effect on patients with severe exercise-
induced bronchoconstriction (defined as
an exercise-induced fall in lung function
>30% from baseline).2
Eight RCTs (5 studying children) were
included in a systematic review of patients
aged >6 years that found no significant dif-
ference between nedocromil and cromo-
glycate with regards to decrease in FEV1,
complete protection, clinical protection, or
side effects.3
Leukotriene antagonists have been 
recommended on a trial basis with fol-
low-up to evaluate the treatment
response.4 Although there are several
long-term studies of leukotriene antago-
nists for adults, few have studied chil-
dren. A recent study assessed the effects
of montelukast (Singulair) on 64 children
with exercise-induced bronchoconstric-
tion. After 8 weeks of treatment, the
montelukast group showed significant
improvements (compared with placebo)
in asthma symptom scores (24.3 ± 8.2
before vs 17.8 ± 6.8 after 8 weeks of
montelukast treatment, P<.05; vs 17.7 ±
6.7 8 weeks after stopping treatment,
P<.05), maximum percent fall in FEV1
after exercise (36.5 ± 10.2% before vs
27.6 ± 14.4% after 8 wks of treatment,
P<.01; vs 26.7 ± 19.4% 8 weeks after
stopping treatment, P<.01), and time to
recovery (41.8 ± 8.1 min before vs 25.3 ±
23.3 min after 8 weeks of treatment,
P<.01; vs 27.7 ± 26.5 min 8 weeks after
stopping, P<.05).5
Therapies awaiting further study
include a combination of budesonide
(Pulmicort) and formoterol (Foradil),
which is similar to the currently available
preparation of fluticasone and salmeterol
(Advair Diskus) but contains a long-acting
beta-agonist with quicker onset. The phos-
phodiesterase-4 inhibitors roflumilast
(Daxas) and cilomilast (Ariflo)—neither of
which have been FDA-approved—and
inhaled low-molecular-weight heparin
have potential efficacy.6 Other options 
suggested for this problem—including
inhaled furosemide, vitamin C, antihista-
mines, calcium channel blockers, and
reduced dietary salt intake—need further
study.7
Recommendations from others
Review articles on this topic suggest the
following to prevent exercise-induced
bronchoconstriction: controlling baseline
asthma, avoiding known allergens, choos-
ing appropriate sports with short bursts of
activity, and selecting warm, humid 
environments for the activities.6–8 Some
authorities recommend warm-up before
athletic events to take advantage of a 30-
to 90-minute refractory period. This can
help prevent exercise-induced broncho-
constriction; however, effects vary consid-
erably from person to person.7,8
Bronchoconstriction
after exercise is
best prevented by
controlling the
underlying asthma,
avoiding allergens,
and choosing
appropriate sports
activities
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The National Asthma Education and
Prevention Program recommends preven-
tion of exercise-induced bronchoconstric-
tion by optimally controlling underlying
asthma. If a patient remains symptomatic
during exercise, you should review medica-
tion usage, understanding of dosage
instructions, and administration technique
before any changes in the treatment 
regimen.9
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